Doxil®--the first FDA-approved nano-drug: lessons learned.

By Y. Barenholz. Journal of Controlled Release, 2012

4,234 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/3ce7c0a98376475fd26396b369ef6d64ce133b8b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. S. Mitragotri
2. A. Anselmo
3. N. Bertrand
4. Xiaoyang Xu
5. O. Farokhzad
6. R. Narayan
7. J. Kulkarni
8. M. Chamundeeswari

In Biomedical Engineering

1. S. Mitragotri
2. A. Anselmo
3. N. Bertrand
4. Xiaoyang Xu
5. J. Kulkarni
6. Phatsapong Yingchoncharoen
7. O. Farokhzad
8. Peng Liu

In Molecular Biology

1. N. Bertrand
2. Xiaoyang Xu
3. S. Mitragotri
4. O. Farokhzad
5. J. Kulkarni
6. Muyue Yang
7. M. Chamundeeswari
8. Phatsapong Yingchoncharoen

Citations in the corpus

• Nanoparticles in the clinic (2016, background): “Doxil, polyethylene glycol (PEG) functionalized liposomal doxorubicin, was the first approved (FDA 1995) cancer nanomedicine.(8) Soon after, other liposomal formulations such as liposomal daunorubicin (DaunoXome),(28) liposomal vincristine (Marqibo),(29) and most recently liposomal irinotecan (Onivy”
• The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment (2020, background): “Several nanodrugs, such as Doxil [25] and Abraxane [26], have been approved by the FDA for clinical use.”
• Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles’ Physicochemical Properties on Responses in Biological Systems (2023, background): “Encapsulation of doxorubicin within the DPPC-based liposome enhances the cytotoxicity of the drug and at the same time suppresses the toxic side effects, thus improving the antitumoural therapeutic efficacy in comparison to conventional doxorubicin [40].”